ABBV-514 monotherapy and in combo with Budigalimab/Bevacizumab in NSCLC, HNSCC, & solid tumors

What is the Purpose of this Study?

What happens in this study?

  • You'll get the study medicine through an IV every 3 weeks
  • Depending on your group, you might also get:
  • Budigalimab (a new medicine being tested)
  • Or a standard cancer medicine
  • You'll give blood and urine samples
  • You'll have regular CT or MRI scans to check your health
What is the Condition Being Studied?

18 years or older with Non-Small Cell Lung Cancer-(NSCLC), Head and Neck Squamous Cell Carcinoma-(HNSCC), Solid Tumors, Gastric/Esophageal, Pancreatic, High-Grade Serous Ovarian Cancer, and Triple Negative Breast Cancer

Who Can Participate in the Study?

Who can join this study?

  • Adults who are 18 or older
  • Have an advanced or spreading form of cancer called a solid tumor
Age Group
Adults

What is Involved?

Why is this study happening?
Doctors want to see if a new medicine called azirkitug (ABBV-514) is safe and works well for people with certain cancers that have spread. They're testing it by itself, or with other medicines like budigalimab or bevacizumab.

Study Details

Full Title
A Global First-in-Human Study in NSCLC, HNSCC, and Solid Tumors with Azirkitug (ABBV‑514) as a Single Agent and in Combination with Budigalimab or Bevacizumab (M24-410)
Principal Investigator
Headshot of John Strickler
Professor of Medicine
Protocol Number
IRB: PRO00118843
NCT: NCT05005403
Phase
Phase I
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL